secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABEONA THERAPEUTICS INC. (ABEO)
CIK:        0000318306
Form:       8-K
Filed at:   2025-07-02T23:59:59+00:00
Accession:  0001641172-25-017460
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.01, 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abeona closes sale of Rare Pediatric Disease PRV for $155M; cash at $225M
-------------------------------------------------------------------------

- Closed sale of Rare Pediatric Disease Priority Review Voucher for $155M gross proceeds on June 27, 2025.
- Unrestricted cash, equivalents, and short-term investments totaled approximately $225M as of June 30, 2025.
- CFO expects over two years of operating capital without further capital infusion; profitability projected early 2026.
- First ZEVASKYN patient treatment anticipated in Q3 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318306/000164117225017460/0001641172-25-017460-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318306/000164117225017460/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-017460

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer